Back

Notification report

Full notification file


General information

Notification Number
B/NL/12/006

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
26/04/2013

Title of the Project
A phase 2b, double-blind, placebo-controlled, multinational, multicenter, randomized study evaluating the safety and efficacy of intracoronary administration of MYDICAR® (AAV1/SERCA2a) in subjects with heart failure (CUPID phase 2b trial)

Proposed period of release:
01/01/2013 to 31/12/2015

Name of the Institute(s) or Company(ies)
Academic Medical Center Amsterdam, the Netherlands, ;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Belgium; Germany; Denmark; United Kingdom; Netherlands; Sweden; Poland;

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Genus: Dependovirus
Species: Adeno-associated virus. The AAV1/SERCA2a vector is a recombinant adeno-associated virus (rAAV) vector. It is a pseudotype of AAV serotype 1(AAV1) and is denoted as rAAV1/2. As such, the capsid proteins are from wt AAV1 and the AAV DNA (two 148 base inverted terminal repeats) is from wtAAV2

Information relating to the recipient or parental organisms from wich the GMO is derived

Common Name	Genus	Species	Subspecies	Strain	Pathovar
AAV1	Dependovirus	Adeno-associated Virus	-	Serotype 1	-

Final report


European Commission administrative information

Consent given by the Member State Competent Authority:
Not known